Adverse Event Reporting
| VAERS ID | 1736741 |
|---|---|
| Gender | Female |
| Age | 78 |
| StateCode | TX |
| Pharmaceutical Company | PFIZER\BIONTECH |
| Lot Number | EN6198 |
| Number of vaccinations | 2 |
| Vaccinated | 2021-03-05 |
| Onset | 2021-08-26 |
| Condition | Hospitalized Died |
Symptoms
- Pyrexia
- Diarrhoea
- Dyspnoea
- Nausea
- Condition aggravated
- Myalgia
- Urinary tract infection
- Back pain
- SARS-CoV-2 test positive
- Influenza A virus test negative
- Influenza B virus test
- COVID-19
- Sepsis
- Staphylococcal infection
- Death
- Computerised tomogram thorax abnormal
- Lung infiltration
- Staphylococcus test positive
- Pulmonary fibrosis
- Escherichia infection
- Blood culture positive
- Bronchiectasis
- Fungal test positive
- Positive airway pressure therapy
Current Illness
UTI one month prior
Preexisting Conditions
Myasthenia, Sarcoma, Dementia
Other Medications
Bactrim DS BID, Ibuprofen 600 mg Q6H PRN, Lidoderm patch PRN, Methocarbamol 500 mg QID, Macrobid BID, Prednisolone 15 mg QOD.
Previous Vaccinations
Allergies
Penicillin, Codeine, Oxycodone
Laboratory Data
COVID-19 Positive 8/31/2021 using Roche LIAT SARS assay platform using PCR or equivalent Nucleic Acid Amplification technology.
Influenza A and B negative
Write-up
Pfizer BioNTech COVID-19 Vaccine EUA: COVID-19 case resulting in Hospitalization / Death.
Patient received Pfizer Vaccines on 2/1/2021 and 3/5/2021.
Patient presented to ED on 8/26/2021 with shortness of breath, after a diagnosis of COVID-19 the day prior.
Patient also has had nausea, diarhhea, diffuse muscle aches and fever as high as 101.
UTI noted and patient was discharged from ED with Bactrim.
Patient returned to ED on 8/31/2021 with complaints of fever, back pain, and O2 sats of 88% subsequently admitted with diagnosis of COVID-19, E.
coli UTI, Severe sepsis with organ dysfunction.
Patient started on ceftriaxone, remdesivir, and steroids.
Blood cultures positive for staph epi 2/2 sets and started on vancomycin.
Cultures cleared with patient placed on Vancomycin.
Patient ultimately required high O2 requirement on HFNC.
She showed some improvements but declined and 9/10 repeat CT chest showed: persistent infiltrates, worsened fibrotic changes and traction bronchiectasis compared to 1.
5 weeks ago.
She also was noted to have a positive fungitell.
She eventually progressed to BiPAP.
Pallitiave care was consulted and patient's MPOA, transitioned to DNR/AND on 9/15.
Comfort care initiated with the assistance of palliative care physician.